162 related articles for article (PubMed ID: 36519636)
21. Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in
Abdallah SM; Hirsh V
Curr Oncol; 2018 Jun; 25(Suppl 1):S9-S17. PubMed ID: 29910643
[TBL] [Abstract][Full Text] [Related]
22. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
[TBL] [Abstract][Full Text] [Related]
23. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
[TBL] [Abstract][Full Text] [Related]
24. Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence.
Ke EE; Wu YL
Ther Adv Respir Dis; 2016 Jun; 10(3):256-64. PubMed ID: 26929305
[TBL] [Abstract][Full Text] [Related]
25. EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
Saxon JA; Sholl LM; Jänne PA
J Thorac Oncol; 2017 May; 12(5):884-889. PubMed ID: 28088511
[TBL] [Abstract][Full Text] [Related]
26. Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation.
Li J; Zhu L; Stebbing J; Peng L
J Cancer Res Ther; 2022 Sep; 18(5):1436-1439. PubMed ID: 36204894
[TBL] [Abstract][Full Text] [Related]
27. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
29. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
Vidal ÓJ
Med Clin (Barc); 2016 Apr; 146 Suppl 1():12-8. PubMed ID: 27426243
[TBL] [Abstract][Full Text] [Related]
30. Role of YES1 amplification in EGFR mutation-positive non-small cell lung cancer: Primary resistance to afatinib in a patient.
Tao J; Sun D; Hou H
Thorac Cancer; 2020 Sep; 11(9):2736-2739. PubMed ID: 32744377
[TBL] [Abstract][Full Text] [Related]
31. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A
Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam.
Vu TH; Nguyen HTT; Dao LK; Duong CK; Nguyen CV; Doan TT; Nguyen HTT; Hoang HH; Dinh DK; Le GV; Vu TT; Truong MC; Nguyen LT
Asian Pac J Cancer Prev; 2021 May; 22(5):1581-1590. PubMed ID: 34048189
[TBL] [Abstract][Full Text] [Related]
33. Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation.
Huang CH; Ju JS; Chiu TH; Huang AC; Tung PH; Wang CC; Liu CY; Chung FT; Fang YF; Guo YK; Kuo CS; Yang CT
Int J Cancer; 2022 Feb; 150(4):626-635. PubMed ID: 34558665
[TBL] [Abstract][Full Text] [Related]
34. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
Gursoy P; Tatli AM; Erdem D; Goker E; Celik E; Demirci NS; Sakin A; Atci MM; Bayram E; Telli TA; Bilgin B; Bilici A; Akangunduz B; Balli S; Demirkazik A; Selçukbiricik F; Menekse S; Cavdar E; Ozturk A; Bekmez ET; Turhal S; Kilickap S; Yildirim HÇ; Oyan B; Aksoy A; Turkoz FP; Kut E; Katgi N; Sakalar T; Akyol M; Ellez Hİ; Topcu A; Erdoğan AP; Pilanci KN; Hedem E; Arak H; Akdeniz N; Alan Ö; Yapar B; Nart D; Yumuk PF
J Cancer Res Clin Oncol; 2023 Feb; 149(2):865-875. PubMed ID: 35381885
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
36. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.
Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot DM; Tan EH; Tanaka H; Wu YL; Yang JC; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N
Lung Cancer; 2019 Jun; 132():126-131. PubMed ID: 31097085
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
[TBL] [Abstract][Full Text] [Related]
38. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6).
Wu YL; Hirsh V; Sequist LV; Hu CP; Feng J; Lu S; Huang Y; Schuler M; Mok T; Yamamoto N; O'Byrne K; Geater SL; Zhou C; Massey D; Märten A; Lungershausen J; Yang JC
Patient; 2018 Feb; 11(1):131-141. PubMed ID: 29178024
[TBL] [Abstract][Full Text] [Related]
39. Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer.
Nishima S; Miyanaga A; Saito S; Yuasa M; Takahashi S; Kashiwada T; Sugano T; Noro R; Minegishi Y; Terasaki Y; Saito Y; Kubota K; Seike M; Gemma A
Intern Med; 2021 Feb; 60(4):591-594. PubMed ID: 32999231
[TBL] [Abstract][Full Text] [Related]
40. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
Huang YH; Hsu KH; Chin CS; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
Cancer Res Treat; 2022 Apr; 54(2):434-444. PubMed ID: 34352999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
